ID   HCC1171
AC   CVCL_5126
SY   HCC-1171; Hamon Cancer Center 1171
DR   BTO; BTO:0006028
DR   EFO; EFO_0003126
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473217
DR   BioSample; SAMN10987756
DR   cancercelllines; CVCL_5126
DR   Cell_Model_Passport; SIDM01553
DR   Cosmic; 903635
DR   Cosmic; 909908
DR   Cosmic; 1146924
DR   DepMap; ACH-000578
DR   EGA; EGAS00001000610
DR   GEO; GSM108857
DR   GEO; GSM108858
DR   GEO; GSM253406
DR   GEO; GSM434258
DR   GEO; GSM794384
DR   GEO; GSM887034
DR   GEO; GSM888104
DR   IARC_TP53; 11447
DR   IGRhCellID; HCC1171GEO
DR   KCLB; 71171
DR   LiGeA; CCLE_622
DR   PharmacoDB; HCC1171_446_2019
DR   PRIDE; PXD002556
DR   Progenetix; CVCL_5126
DR   Wikidata; Q54881534
RX   PubMed=9559342;
RX   PubMed=10353731;
RX   PubMed=10987304;
RX   PubMed=20679594;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26361996;
RX   PubMed=26589293;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Doubling time: 47.5 hours (PubMed=29681454).
CC   HLA typing: A*02:01,03:01; B*40:01,40:01; C*02:02,03:04; DQA1*01:04,03:02; DQB1*03:04,05:03; DRB1*03:17,14:07 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=10353731; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn247Ile (c.740A>T); ClinVar=VCV000184882; Zygosity=Homozygous (PubMed=10353731; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.8%; Native American=0%; East Asian, North=0.4%; East Asian, South=0%; South Asian=0%; European, North=65.59%; European, South=32.21% (PubMed=30894373).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
ST   Source(s): KCLB; PubMed=20679594; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 11
ST   D16S539: 14
ST   D18S51: 16
ST   D21S11: 30,31
ST   D3S1358: 14,16
ST   D5S818: 11
ST   D7S820: 9,12
ST   D8S1179: 12,13
ST   FGA: 20,25
ST   Penta D: 11,12
ST   Penta E: 14
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S842 ! HCC1171 BL
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 30
//
RX   PubMed=9559342; DOI=10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2;
RA   Virmani A.K., Fong K.M., Kodagoda D.R., McIntire D., Hung J., Tonk V.,
RA   Minna J.D., Gazdar A.F.;
RT   "Allelotyping demonstrates common and distinct patterns of chromosomal
RT   loss in human lung cancer types.";
RL   Genes Chromosomes Cancer 21:308-319(1998).
//
RX   PubMed=10353731;
RA   Wistuba I.I., Bryant D., Behrens C., Milchgrub S., Virmani A.K.,
RA   Ashfaq R., Minna J.D., Gazdar A.F.;
RT   "Comparison of features of human lung cancer cell lines and their
RT   corresponding tumors.";
RL   Clin. Cancer Res. 5:991-1000(1999).
//
RX   PubMed=10987304;
RA   Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.;
RT   "Genome-wide allelotyping of lung cancer identifies new regions of
RT   allelic loss, differences between small cell lung cancer and non-small
RT   cell lung cancer, and loci clustering.";
RL   Cancer Res. 60:4894-4906(2000).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//